Our very own Prof. Kim Kuypers talks about the psychedelic research carried out at our department for DOCS! Click on the link to listen to the Trip Generation episode (in Dutch).
Since about 20 years, smoking mixtures, such as Spice or K2, have become popular alternatives for cannabis. These smoking mixtures contain synthetic cannabinoids, which are reported to cause more psychological problems and stronger behavioral impairment. However, comparing the effects of synthetic cannabinoids with natural cannabis has been problematic due to the differences in pharmacological properties… Continue reading A comparison of acute neurocognitive and psychotomimetic effects of a synthetic cannabinoid and natural cannabis at psychotropic dose equivalence
The growing availability and variability of novel psychedelics present new challenges for drug policy, as well as opportunities for clinical research. However, unlike their classic derivatives like psilocybin or lsd, little is known about these drugs. Using an online questionnaire, we asked people what novel psychedelic substances they were using, and what they were experience.… Continue reading The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides
New study from our group assessed cognitive and subjective effects of a synthetic cannabinoid, JWH-018. Read coverage of the publication from Live Science.
March 25, 2019. Researchers from IMIM (Barcelona) and our department employed the quantification of monoamine neurotransmitters and steroid hormones in brain tissue and blood of rats to predict the pharmacological similarity of NPS to classical drugs of abuse. The metabolomics approach in animals improves the speed of NPS classification.